Sugi Predict

Sugi Predict / Compounds / SCHEMBL1286940

SCHEMBL1286940

SCHEMBL1286940

COC(=O)C=Cc1ccco1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 10/20 0.67
▸ MEN1 O00255 5/20 0.67
▸ KMT2A Q03164 5/20 0.67
▸ ALDH1A1 P00352 6/20 0.64
▸ L3MBTL1 Q9Y468 4/20 0.64
▸ HCAR2 Q8TDS4 1/20 0.62
▸ CACNA1B Q00975 1/20 0.59
▸ APBA1 Q02410 1/20 0.59
▸ MAPT P10636 3/20 0.58
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ TDP1 Q9NUW8 5/20 0.57
▸ APEX1 P27695 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ BLM P54132 1/20 0.55
▸ MCL1 Q07820 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ GLA P06280 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1286936 1.00 POLB (0.67) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7141083 0.85 HCAR2 (0.67) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7141082 0.85 HCAR2 (0.67) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL1408805 0.84 HCAR2 (0.65) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7138125 0.83 POLB (0.60) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7138121 0.83 POLB (0.60) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL2761714 0.81 MAPT (0.53) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL23175323 0.81 POLB (0.59) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL336288 0.81 POLB (0.59) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL8104407 0.81 MAPT (0.63) POLBMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114502667-A Coating composition and laminate comprising coating 株式会社东进世美肯 2022-05-13 — — CN claimed
US-8916683-B2 Nanostructured physically-associating hydrogels for injectable, responsive, and tough biomaterials MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-12-23 — — US claimed
US-20140024722-A1 Nanostructured Physically-Associating Hydrogels for Injectable, Responsive, and Tough Biomaterials MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-01-23 — — US claimed
WO-2012048009-A2 NANOSTRUCTURED PHYSICALLY-ASSOCIATING HYDROGELS FOR INJECTABLE, RESPONSIVE AND TOUGH BIOMATERIALS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-04-12 — — WO claimed
WO-2023042894-A1 FURANACRYLIC ACID ESTER POLYMER, PRODUCTION METHOD THEREFOR, AND POLYMERIZABLE MONOMER FOR USE IN PRODUCING SAID POLYMER AND PRODUCTION METHOD THEREFOR 国立研究開発法人産業技術総合研究所 2023-03-23 — — WO disclosed
CN-112708056-B Viscosity-reducing polycarboxylate superplasticizer for concrete member and preparation method thereof 科之杰新材料集团河南有限公司 2022-10-18 — — CN disclosed
CN-114502667-A Coating composition and laminate comprising coating 株式会社东进世美肯 2022-05-13 — — CN disclosed
CN-112708056-A Viscosity-reducing polycarboxylate superplasticizer for concrete member and preparation method thereof 科之杰新材料集团河南有限公司 2021-04-27 — — CN disclosed
WO-2021066628-A1 COATING COMPOSITION AND LAMINATE COMPRISING COATING LAYER 주식회사 동진쎄미켐 2021-04-08 — — WO disclosed
US-8916683-B2 Nanostructured physically-associating hydrogels for injectable, responsive, and tough biomaterials MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-12-23 — — US disclosed
US-20140024722-A1 Nanostructured Physically-Associating Hydrogels for Injectable, Responsive, and Tough Biomaterials MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-01-23 — — US disclosed
CN-102655912-A Foam hair colorant composition PROCTER & GAMBLE 2012-09-05 — — CN disclosed
CN-1305993-A Cyclic guanyl preparation used as nitrogen oxide synthetic enzyme inhibitor SEARLE & CO (US) 2001-08-01 — — CN disclosed
CN-1299282-A Vitronectin receptor antagonists SMITHKLINE BEECHAM CORP (US) 2001-06-13 — — CN disclosed
EP-1061921-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-27 — — EP disclosed
US-6011028-A Cyclic amidino agents useful as nitric oxide synthase inhibitors G.D. SEARLE & CO. (US) 2000-01-04 — — US disclosed
WO-1999045927-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-09-16 — — WO disclosed
CN-1189823-A Cyclic amidino formulations useful as nitric oxide synthase inhibitors SEARLE & CO (US) 1998-08-05 — — CN disclosed
EP-0821674-A1 CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1998-02-04 — — EP disclosed
US-4263212-A Process for preparation of substituted olefins RIKAGAKU KENKYUSHO (JP) 1981-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024722-A1 Nanostructured Physically-Associating Hydrogels for Injectable, Responsive, and Tough Biomaterials MSN, CD44, IGFBP4 POLB 3557/4885MEN1 2349/4885KMT2A 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.